drugset / Trial / NCT02233244
Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam
NaSingle-groupOpen-labelBasic science
Summary
This drug-drug interaction study will assess the potential of CTX-4430 to induce CYP3A activity in healthy subjects. The study hypothesis is that midazolam (a sensitive, widely used CYP3A4 substrate) blood levels will not change after treatment with CTX-4430.
Timeline
- Start
- 2014-09
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acebilustat | Small molecule | 100 mg | — |
| Subject | Midazolam | Small molecule | 2 mg | — |
Indications
No indication recorded.